September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
5 citations
,
February 2014 in “Journal of Liquid Chromatography & Related Technologies” Method accurately measures finasteride and tamsulosin in combined drug form.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology” July 2025 in “Journal of Investigative Dermatology” Spironolactone can safely lower blood pressure in patients on other blood pressure medications, but may slightly increase the risk of low blood pressure.
Restolin Hair Supplement may help hair growth but lacks FDA approval and clinical trial evidence.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
November 2023 in “SKIN The Journal of Cutaneous Medicine” 1 citations
,
July 2025 in “Functional Foods in Health and Disease” CL22209, an Asparagus racemosus extract, safely reduces perimenopausal symptoms and balances hormones.
New acne treatments like clascoterone and minocycline foam are effective, and using antibiotics carefully is important to avoid resistance.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
September 2024 in “Journal of the American Academy of Dermatology” Semaglutide does not significantly increase the risk of hair loss.
2 citations
,
November 2024 in “AAPS PharmSciTech” Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
November 2013 in “The Journal of Urology” 8 citations
,
January 2025 in “Gels” The developed nasal gel improves cilostazol delivery to the brain, enhancing its effectiveness and reducing side effects.
November 2023 in “Circulation” Minoxidil can cause a rare but serious condition that leads to fluid buildup around the heart and drug-induced lupus.
October 2024 in “Irish Journal of Medical Science (1971 -)” Electrical stimulation with a low-calorie diet reduces appetite, weight, and blood pressure in obese people with sleep apnea.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
39 citations
,
November 2015 in “Pediatric Nephrology” Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
March 2024 in “Journal of the American Academy of Dermatology”
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
A medicine company has recalled a drug because it contained an unlisted blood pressure medication.
April 2018 in “Journal of Investigative Dermatology” Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
November 2025 in “Frontiers in Pharmacology” Xiaozhi Yufa decoction may help treat hair loss by improving hair growth and reducing inflammation.
January 2007 in “Zhōnghuá yàoxué zázhì” The method effectively showed that the two exemestane preparations are bioequivalent.
1 citations
,
December 2016 JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
36 citations
,
February 2021 in “Clinical Nutrition” Resveratrol improved menstrual regularity and reduced hair loss in women with PCOS.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
October 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Protetox is claimed to be an effective weight loss supplement with positive reviews.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.